featured
Antiviral Therapy Substantially Reduces HCC Risk in Patients With Chronic Hepatitis B in the Indeterminate Phase
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Hepatology (Baltimore, Md.)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase
Hepatology 2023 Nov 01;78(5)1558-1568, DQ Huang, A Tran, ML Yeh, S Yasuda, PC Tsai, CF Huang, CY Dai, E Ogawa, M Ishigami, T Ito, R Kozuka, M Enomoto, T Suzuki, Y Yoshimaru, CM Preda, RI Marin, I Sandra, S Tran, SXZ Quek, HHTW Khine, N Itokawa, M Atsukawa, H Uojima, T Watanabe, H Takahashi, K Inoue, M Maeda, JK Hoang, L Trinh, S Barnett, R Cheung, SG Lim, HN Trinh, WL Chuang, Y Tanaka, H Toyoda, ML Yu, MH NguyenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.